Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Status:
RECRUITING
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.